Malignant Fibrous Histiocytoma of Soft Tissue is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Malignant Fibrous Histiocytoma of Soft Tissue have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Malignant Fibrous Histiocytoma of Soft Tissue compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Malignant Fibrous Histiocytoma of Soft Tissue overview

Malignant fibrous histiocytoma (MFH), now known as undifferentiated pleomorphic sarcoma, is a type of cancerous tumor that originates in the bone or soft tissue or other organ parts of the body. It is the most common form of soft tissue tumors generally seen in adults and very rarely in children. It is a painless mass believed to originate from primitive mesenchymal cells arising from soft tissue or bone, usually in the extremities or retroperitoneum. It can occur in any part of the body and may metastasize to lungs, lymph nodes, and bones. The etiology is still unknown, but radiation exposure is believed to be one of the common causes of this condition. Diagnosis is done by MRI and CT scan. Treatment is either surgery or radiotherapy.

For a complete picture of PTSR and LoA scores for drugs in Malignant Fibrous Histiocytoma of Soft Tissue, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.